In the present study, we aimed to demonstrate that FBPA PET was useful for evaluating the early response of anti-PD-1 cancer immunotherapy in B16F10 melanoma-bearing mice, comparing the results with those of FDG PET. The gene discussed is RPL17; the disease is melanoma.